Pricing Log in Create free account
Saturday 17 October 2026 Export WST’s income statement to Excel — free account

West Pharmaceutical Services, Inc.

WST Healthcare Medical Instruments & Supplies

West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

382.92 0.10 −0.03%
Market cap
$27.0B
P/E
48.7×
Fwd P/E
37.3×
Dividend yield
0.23%
F-score
8/9
Altman Z
13.89
Beneish M
−2.79
Dividend safety
100/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 6.57
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — 2 — — — — 2 —
Insider Ownership 1.34%

Capital & Financial Ratios $m

Market Cap 26,960.00
Revenue 3,326.80
Net Income 564.90
Free Cash Flow 436.90
Net Debt (232.90)
Current Ratio 2.82 (at or above 1.5: strong)
Debt/Equity 0.07 (at or below 0.5: strong)
P/E ratio 48.66 (above 35: high)
Fwd P/E 37.30 (above 35: high)
P/S ratio 8.15
P/B ratio 9.07 (above 6: high)
Past 5Y EPS Growth 8.24%
This Y EPS Growth 23.15% (at or above 15%: strong)
Next Y EPS Growth 11.68%
Next Y revenue growth 9.79%
Next 5Y EPS Growth 16.27% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 8.1×, against a ten-year median of 6.2×; over the ten years it ranged from 2.9× in 2016 to 13.1× in 2021.
P/E against its own 10 years 65.98%
10-year low 10-year high
P/S against its own 10 years 67.16%
10-year low 10-year high
P/B against its own 10 years 67.16%
10-year low 10-year high
EV/Sales against its own 10 years 68.12%
10-year low 10-year high
EV/FCF against its own 10 years 52.89%
10-year low 10-year high

Dividends

Payout Ratio 0.11
Annual Dividend Rate 0.88
Annual Dividend Yield 0.23%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.85
0.22
0.22
0.22
2025 0.85
0.21
0.21
0.21
0.22
2024 0.81
0.20
0.20
0.20
0.21
2023 0.77
0.19
0.19
0.19
0.20
2022 0.73
0.18
0.18
0.18
0.19
2021 0.69
0.17
0.17
0.17
0.18
2020 0.65
0.16
0.16
0.16
0.17
2019 0.61
0.15
0.15
0.15
0.16
2018 0.57
0.14
0.14
0.14
0.15
2017 0.53
0.13
0.13
0.13
0.14
2016 0.49
0.12
0.12
0.12
0.13
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 854 485 791 436
Receivables 512 553 574 712
Inventory 435 377 444 447
Other 136 124 169 212
1,936 1,538 1,978 1,808
2023 2024 2025 Q'26
Payables 242 239 254 253
ST’ Debt — — — —
Other 155 188 215 171
672 550 655 641

Compound Annual Growth %

10y 5y 3y
Sales 8.18% 7.44% 2.12%
Cash Flow 13.52% 9.82% 1.40%
Earnings 17.84% 7.36% (5.55%)
Book Value 11.99% 11.36% 5.76%

Revenue $m

Mar Jun Sep Dec Year
’26 845 872 — — —
’25 698 767 805 805 3,074
’24 695 702 747 749 2,893
’23 717 754 747 732 2,950
’22 720 771 687 709 2,887
’21 671 724 707 731 2,832
’20 492 527 548 580 2,147
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 90 124 — — —
’25 129 177 197 251 755
’24 118 165 180 190 653
’23 138 169 230 239 777
’22 151 173 169 231 724
’21 89 144 190 161 584
’20 57 148 119 149 473
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 47 81 — — —
’25 58 102 134 175 469
’24 28 65 99 85 276
’23 56 94 134 130 415
’22 85 107 111 136 439
’21 34 88 125 84 331
’20 25 107 71 91 298
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 1.92 2.15 — — —
’25 1.23 1.82 1.92 1.82 6.79
’24 1.55 1.51 1.85 1.78 6.69
’23 1.85 2.06 2.14 1.83 7.88
’22 2.29 2.48 1.59 1.36 7.73
’21 1.99 2.47 2.31 1.93 8.67
’20 0.99 1.21 1.09 1.29 4.57
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 53.88 77.97 82.74 93.08 124.53 253.86 206.19 225.66 265.00 187.43

Analyst estimates 2026–2028

Powerpack
High 86.50 103.36 125.09 152.12 305.00 475.35 468.05 415.73 413.70 348.90
People
People Employees 7,100 7,500 7,700 8,200 9,200 10,065 13,550 10,600 10,600 10,800
Revenue/emp, $m 0.21 0.21 0.22 0.22 0.23 0.28 0.21 0.28 0.27 0.28
Income, $m
Income, $m Revenue 1,509 1,599 1,717 1,840 2,147 2,832 2,887 2,950 2,893 3,074
Gross margin, % 33.23 32.07 31.76 32.92 35.76 41.52 39.36 38.28 34.51 35.91
EBT 190 222 241 292 401 749 680 698 586 601
EBT margin, % 12.58 13.91 14.02 15.86 18.69 26.45 23.55 23.66 20.24 19.55
Net income 144 151 207 242 346 662 586 593 493 494
Depreciation 91 97 104 103 109 122 121 137 155 171
Per share, $
Per share, $ Revenue 20.59 21.64 23.24 24.86 29.05 38.06 38.80 39.70 39.63 42.52
Earnings 1.96 2.04 2.80 3.27 4.68 8.89 7.87 7.98 6.75 6.83
Cash flow 2.99 3.56 3.91 4.96 6.39 7.85 9.73 10.45 8.95 10.44
Capex (2.32) (1.77) (1.42) (1.71) (2.36) (3.41) (3.83) (4.87) (5.16) (3.95)
Free cash flow 0.67 1.79 2.49 3.25 4.03 4.44 5.91 5.58 3.79 6.49
Book value 15.25 17.32 18.89 21.26 25.09 31.39 36.09 38.78 36.74 43.93
Shares, m 73 74 74 74 74 74 74 74 73 72
Valuation, ×
Valuation, × P/E 42.89 48.54 35.01 45.97 60.41 52.58 29.79 43.70 48.53 40.28
P/S 4.08 4.60 4.22 6.05 9.75 12.32 6.04 8.78 8.26 6.47
P/B 5.51 5.75 5.19 7.07 11.29 14.94 6.50 8.99 8.91 6.26
EV/Sales 4.10 4.57 4.14 5.95 9.58 12.13 5.80 8.52 8.17 6.28
EV/FCF 131.89 56.18 39.11 45.60 69.91 105.08 38.46 61.18 86.68 41.51
Cash, $m
Cash, $m Operating cash flow 219 263 289 367 473 584 724 777 653 755
Capex (170) (131) (105) (126) (174) (253) (285) (362) (377) (286)
Free cash flow 49 133 184 241 298 331 439 415 276 469
Balance, $m
Balance, $m Working capital 401 464 611 717 870 1,148 1,401 1,265 988 1,323
Total debt 226 197 196 255 253 209 207 73 203 203
Net debt 23 (39) (141) (184) (363) (554) (688) (781) (282) (588)
Shareholders’ equity 1,118 1,280 1,396 1,573 1,855 2,335 2,685 2,881 2,682 3,176
Returns, %
Returns, % ROA 8.42 8.42 10.77 11.19 13.48 21.67 16.91 15.94 13.19 12.48
ROIC 10.70 11.37 11.97 13.34 17.05 26.39 22.97 20.12 14.84 14.13
ROE 13.41 12.57 15.46 16.28 20.20 31.59 23.34 21.32 17.71 16.85
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

West Pharmaceutical Services, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BDX Becton, Dickinson and Company $52.8B 57.8× 37.7× +5.44% (above 0%: growing) −31.50% (below 0%: shrinking) −31.57% (below 0%: shrinking) 46.46% 13.31% Compare
MDLN Medline Inc. $48.1B — — +15.67% (above 0%: growing) — +3.42% (above 0%: growing) 28.82% 5.14% Compare
RMD ResMed Inc. $34.1B 22.8× 16.6× +8.58% (above 0%: growing) +2.32% (above 0%: growing) −21.31% (below 0%: shrinking) 58.84% 30.66% Compare
ALC Alcon $32.1B 50.5× 31.0× +8.74% (above 0%: growing) n/m −0.54% (below 0%: shrinking) 59.33% 0.39% Compare
WST West Pharmaceutical Services, Inc. $27.0B 48.7× 37.3× +13.80% (above 0%: growing) +19.23% (above 0%: growing) −20.71% (below 0%: shrinking) 37.74% 20.53%
SOLV Solventum Corporation $15.0B 10.4× 39.0× +2.22% (above 0%: growing) +1.92% (above 0%: growing) +144.07% (above 0%: growing) 58.22% 8.19% Compare
BAX Baxter International Inc. $13.3B — (loss-making) 44.7× +5.34% (above 0%: growing) +33.33% (above 0%: growing) +119.48% (above 0%: growing) 34.86% 7.33% Compare
RGEN Repligen Corporation $11.7B 234× 112× +11.93% (above 0%: growing) −65.38% (below 0%: shrinking) +27.10% (above 0%: growing) 53.91% 6.85% Compare
COO The Cooper Companies, Inc. $10.9B 19.8× 28.7× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
Median of peers $23.5B 36.7× 37.7× +7.01% +2.12% +15.26% 56.07% 7.76%

All 55 Medical Instruments & Supplies stocks →

WST metrics, ten years each

West Pharmaceutical Services, Inc. (WST) key facts

  • Strength: West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
  • West Pharmaceutical Services, Inc. (WST) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
  • Net income was $493.7 million, or $6.83 per share (basic), a net margin of 16.1%.
  • As of October 16, 2026, WST traded at $382.92, a market capitalization of $27.0 billion.
  • At that price the stock trades at 48.7× trailing-twelve-month earnings and 8.1× sales; its P/E is higher than 66% of its own readings over the past ten years.
  • West Pharmaceutical Services, Inc. pays an annual dividend of $0.88 per share, a yield of 0.23%, with a payout ratio of 11.3%.
  • Return on equity was 16.9% and debt-to-equity 0.07.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 13.89 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

West Pharmaceutical Services, Inc. (WST) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/WST · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com